Pfizer enters 2026 facing earnings pressure from COVID revenue collapse and acquisition-related dilution. Click here to read ...

Pfizer is playing catch-up in the crowded field of obesity medicines, but it hoped to compete with a daily pill alternative to currently available injectable GLP-1 products. Instead, Pfizer is ...

I reaffirm my Buy rating on Pfizer due to expected promising updates on danuglipron and strong capital efficiency metrics, despite the recent stock pullback. Pfizer's management is expected to ...

Pfizer's Q3 earnings fell, but the company still raised its full-year earnings guidance. Major cost reductions remain on track, which should significantly boost the drugmaker's bottom line. Pfizer's ...

Bank of America (BofA) Securities updated the earnings model for Pfizer Inc. (NYSE:PFE). The company will announce second-quarter 2025 earnings on August 5. According to data from Benzinga Pro, ...

April 14 (UPI) --Pfizer on Monday announced it is halting development of a daily weight loss pill after one patient experienced a liver injury and previous problems with other pill versions. The ...

Pfizer's third-quarter sales fell 6% year over year to $16.65 billion, beating the consensus of $16.59 billion. The revenue reflected an operational decline of 7%. The operational decrease was ...

First in the industry sustainability bond provides opportunities to invest in projects supporting environmental sustainability and health of vulnerable populations Supports United Nations Sustainable ...

Pfizer has agreed to acquire Metsera, a clinical-stage biopharmaceutical company. The transaction, announced Sept. 22, is valued at $47.50 per Metsera share in cash upon closing, for an initial ...